Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > AION to Catch Up to Others!

<< Previous

Bullboard Posts

Next >>

Comment by auricgoldon Dec 20, 2020 2:10pm

170 Views

Post# 32149429

RE:RE:AION to Catch Up to Others!

I feel that after the PP and the reverse are completed, this will fly in the next 4 months or so. im in at 0.015.

famar wrote: You're right about that for sure, big things to come at least HEM have their past studies in hand. Players in the stock will continue to play. What will be important is having a good partner who would take the product to market.

GLTA....fmb

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions